RecruitingPhase 2NCT07321951

A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

A Multicenter, Randomized, Double-blind, Phase II Study to Evaluate the Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd

Enrollment

200 participants

Start Date

Jan 9, 2026

Study Type

INTERVENTIONAL

Conditions

Moderate-to-severe Atopic Dermatitis

Summary

This trial was designed to evaluate the efficacy and safety of SHR-1819 in adult patients with moderate-to-severe atopic dermatitis.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called SHR-1819 Injection and a drug called SHR-1819 Injection Blank Preparation for people with moderate-to-severe atopic dermatitis. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSHR-1819 Injection

SHR-1819 injection.

DRUGSHR-1819 Injection Blank Preparation

SHR-1819 injection blank preparation.

Locations(2)

Dermatology Hospital of Southern Medical University

Guangzhou, Guangdong, China

Hangzhou Third People's Hospital

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07321951

Related Trials

Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis

NCT0693425215 locations

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

NCT0755866814 locations

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

NCT072115421 location

Efficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis.

NCT0623931130 locations

Phase III Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis

NCT067230801 location